白细胞介素-6、托珠单抗与动脉粥样硬化。对格拉西莫娃等人的评论。白细胞介素-6：类风湿关节炎患者长期细胞因子抑制的心血管方面。2024年，，12425。
Interleukin-6, Tocilizumab and Atherosclerosis. Comment on Gerasimova et al. Interleukin-6: Cardiovascular Aspects of Long-Term Cytokine Suppression in Patients with Rheumatoid Arthritis. 2024, , 12425.
作者信息
Saleh Christian, Budincevic Hrvoje
机构信息
Independent Researcher, 4056 Basel, Switzerland.
Department of Neurology, Sveti Duh University Hospital, 10000 Zagreb, Croatia.
出版信息
Int J Mol Sci. 2025 Mar 25;26(7):2952. doi: 10.3390/ijms26072952.
Abstract
Gerasimova et al. [...].
摘要
杰拉西莫娃等人[……]
相似文献
1
Interleukin-6, Tocilizumab and Atherosclerosis. Comment on Gerasimova et al. Interleukin-6: Cardiovascular Aspects of Long-Term Cytokine Suppression in Patients with Rheumatoid Arthritis. 2024, , 12425.白细胞介素-6、托珠单抗与动脉粥样硬化。对格拉西莫娃等人的评论。白细胞介素-6：类风湿关节炎患者长期细胞因子抑制的心血管方面。2024年，，12425。
Int J Mol Sci. 2025 Mar 25;26(7):2952. doi: 10.3390/ijms26072952.
2
Reply to Saleh, C.; Budincevic, H. Interleukin-6, Tocilizumab and Atherosclerosis. Comment on "Gerasimova et al. Interleukin-6: Cardiovascular Aspects of Long-Term Cytokine Suppression in Patients with Rheumatoid Arthritis. 2024, , 12425".对萨利赫、C.；布丁采维奇、H.的回复。白细胞介素-6、托珠单抗与动脉粥样硬化。对“格拉西莫娃等人。白细胞介素-6：类风湿性关节炎患者长期细胞因子抑制的心血管方面。2024年，，12425”的评论。
Int J Mol Sci. 2025 Mar 25;26(7):2953. doi: 10.3390/ijms26072953.
3
Interleukin-6 and cytochrome-P450, reason for concern?白细胞介素-6 和细胞色素 P450，值得关注的原因？
Rheumatol Int. 2012 Sep;32(9):2601-4. doi: 10.1007/s00296-012-2423-3. Epub 2012 Mar 27.
4
Biologic interventions for fatigue in rheumatoid arthritis.类风湿关节炎疲劳的生物干预措施。
Cochrane Database Syst Rev. 2016 Jun 6;2016(6):CD008334. doi: 10.1002/14651858.CD008334.pub2.
5
Differential effects of inhibition of interleukin 1 and 6 on myocardial, coronary and vascular function.白介素 1 和 6 抑制对心肌、冠脉和血管功能的差异影响。
Clin Res Cardiol. 2019 Oct;108(10):1093-1101. doi: 10.1007/s00392-019-01443-9. Epub 2019 Mar 11.
6
Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.生物制剂或托法替布用于对甲氨蝶呤或其他传统改善病情抗风湿药物反应不完全的类风湿关节炎患者：一项系统评价和网状Meta分析
Cochrane Database Syst Rev. 2016 May 13;2016(5):CD012183. doi: 10.1002/14651858.CD012183.
7
Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement.阻断白介素-6 在类风湿关节炎和其他炎症性风湿病中的作用：系统文献回顾和荟萃分析为共识声明提供信息。
Ann Rheum Dis. 2013 Apr;72(4):583-9. doi: 10.1136/annrheumdis-2012-202470. Epub 2012 Nov 10.
8
Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor.托珠单抗治疗类风湿关节炎的系统评价：一种针对白细胞介素-6 受体的新型生物制剂。
Clin Ther. 2012 Apr;34(4):788-802.e3. doi: 10.1016/j.clinthera.2012.02.014. Epub 2012 Mar 22.
9
Inhibiting interleukin-6 in rheumatoid arthritis.抑制类风湿关节炎中的白细胞介素-6
Curr Rheumatol Rep. 2008 Oct;10(5):413-7. doi: 10.1007/s11926-008-0066-x.
10
Interleukin-6: Cardiovascular Aspects of Long-Term Cytokine Suppression in Patients with Rheumatoid Arthritis.白介素-6：类风湿关节炎患者长期细胞因子抑制的心血管方面。
Int J Mol Sci. 2024 Nov 19;25(22):12425. doi: 10.3390/ijms252212425.
本文引用的文献
1
Interleukin-6: Cardiovascular Aspects of Long-Term Cytokine Suppression in Patients with Rheumatoid Arthritis.白介素-6：类风湿关节炎患者长期细胞因子抑制的心血管方面。
Int J Mol Sci. 2024 Nov 19;25(22):12425. doi: 10.3390/ijms252212425.
2
Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis.生物疗法对类风湿关节炎患者血脂谱和胰岛素抵抗的显著影响。
Arthritis Res Ther. 2015 Mar 7;17(1):52. doi: 10.1186/s13075-015-0559-8.
3
Association of interleukin-6 with the progression of carotid atherosclerosis: a 9-year follow-up study.白细胞介素-6与颈动脉粥样硬化进展的关联：一项9年随访研究。
Stroke. 2014 Oct;45(10):2924-9. doi: 10.1161/STROKEAHA.114.005991. Epub 2014 Aug 19.
4
Changes in carotid intima-media thickness during the cardiac cycle: the multi-ethnic study of atherosclerosis.颈动脉内膜中层厚度在心动周期中的变化：动脉粥样硬化的多民族研究。
J Am Heart Assoc. 2012 Aug;1(4):e001420. doi: 10.1161/JAHA.112.001420. Epub 2012 Aug 24.
5
Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011.曼海姆颈动脉内膜中层厚度和斑块共识（2004-2006-2011）。代表第三届、第四届和第五届观察风险研讨会顾问委员会在德国曼海姆第 13 届、第 15 届和第 20 届欧洲卒中会议，比利时布鲁塞尔，2006 年和德国汉堡，2011 年更新。
Cerebrovasc Dis. 2012;34(4):290-6. doi: 10.1159/000343145. Epub 2012 Nov 1.
6
Variations in common carotid artery intima-media thickness during the cardiac cycle: implications for cardiovascular risk assessment.心动周期中颈总动脉内中膜厚度的变化：对心血管风险评估的影响。
J Am Soc Echocardiogr. 2012 Sep;25(9):1023-8. doi: 10.1016/j.echo.2012.05.007. Epub 2012 Jun 20.
7
Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial.托珠单抗单药治疗可有效降低类风湿关节炎患者的动脉僵硬程度，与依那西普或阿达木单抗单药治疗效果相当：一项开放标签随机对照试验。
J Rheumatol. 2011 Oct;38(10):2169-71. doi: 10.3899/jrheum.110340. Epub 2011 Aug 1.
8
Inter-reader differences in common carotid artery intima-media thickness: implications for cardiovascular risk assessment and vascular age determination.颈总动脉内中膜厚度的读者间差异：对心血管风险评估和血管年龄测定的影响。
J Ultrasound Med. 2011 Jul;30(7):915-20. doi: 10.7863/jum.2011.30.7.915.
9
Asymmetrical distribution of atherosclerosis in the carotid artery: identical patterns across age, race, and gender.颈动脉粥样硬化的不对称分布：在年龄、种族和性别方面具有相同的模式。
Eur J Prev Cardiol. 2012 Aug;19(4):687-97. doi: 10.1177/1741826711410821. Epub 2011 May 25.
10
Effect of inter-reader variability on outcomes in studies using carotid intima media thickness quantified by carotid ultrasonography.颈动脉超声定量检测颈动脉内膜中层厚度研究中观察者间变异性对结果的影响。
Eur J Epidemiol. 2010 Jun;25(6):385-92. doi: 10.1007/s10654-010-9442-8. Epub 2010 Mar 23.
Zotero 插件